Skip to main content

Table 1 Extended cost-effectiveness analysis input parameters for public financing of selected malaria prevention and treatment interventions in Ethiopia

From: Health gains and financial risk protection afforded by public financing of selected malaria interventions in Ethiopia: an extended cost-effectiveness analysis

ParameterValueReferences
Epidemiology
 Population at risk of malaria (2016)61,504,000[12, 38]
 Population for malaria vaccine (2016 birth cohort)1,984,000Authors’ calculation [34, 38]
 Crude birth and child mortality rate, per 1000 population32, 20[34]
 Total fertility rate, Q1–Q5; Aa6.4, 5.6, 4.9, 4.3, 2.6; 4.6[34]
 Average household size4.2[38]
 Number of malaria deaths in the general population, population at risk, and children5000; 3767; 1790[4, 39]
 Prevalence of malaria in population at risk, Q1–Q5; A4.6; 3.1; 3.6; 2.2; 2.1; 3.1%[9, 10]
 Prevalence of malaria in children, Q1–Q5; A5, 3.3, 2.9, 2, 1.7, 3.1%[9]
 Probability of seeking malaria care, Q1–Q5; A23.8, 30.4, 33.0, 42.3, 50.5; 35.3%[34]
 Case fatality ratio for malaria outpatient and inpatient cases0.19; 0.65%[3, 4]
 Proportion of malaria-related hospital admissions, Q1–Q51.00, 0.90, 0.96, 0.87, 0.83; 0.91%[36, 37]
 Effectiveness of LLIN50%[27, 40]
 Effectiveness of indoor residual spraying (IRS)29%[31]
 Vaccine efficacy, Weibull decay after 9 months over 5-years9–12 months77%Authors’ calculation based on [41]
12–24 months46%
24–36 months23%
36–48 months13%
48–60 months8%
 Effectiveness of artemisinin combination therapy (ACT) on mortality reduction95%[32]
Interventions
 LLIN coverage before intervention, Q1–Q5, A26, 36, 42, 47, 44; 40%[9]
 LLIN coverage after intervention, Q1–Q5, A36, 46, 52, 57, 54; 50%[12] Authors’ assumption
 IRS coverage before intervention, Q1–Q5, A35, 35, 36, 28, 11; 29%[9]
 IRS coverage after intervention, Q1–Q5, A45, 45, 46, 38, 21; 39%[12] Authors’ assumption
 Malaria vaccine coverage before intervention, Q1–Q5, A0[15]
 Malaria vaccine coverage after intervention, Q1–Q5, A10, 10, 10, 10, 10; 10%Authors’ assumption
 Malaria vaccine coverage after intervention, Q1–Q5, A (fully immunized coverage)19, 31, 30, 40, 58; 33%[34]
 ACT coverage before intervention, Q1–Q5, A24, 30, 33, 42, 51; 35%[34]
 ACT coverage after intervention, Q1–Q5, A34, 40, 43, 52, 61; 45%Authors’ assumption
Costs (2016 $)
 Out-of-pocket outpatient costs, Q1–Q5, A$6.4, 6.8, 5.5, 6.6, 5.7; 6.2[42]
 Out-of-pocket inpatient costs$65.9[18]
 Unit cost of malaria treatment outpatient visit$7.3[43]
 Unit cost of malaria treatment inpatient visitb$31.6[43]
 Unit cost of LLIN$5.4[44]
 Unit cost per vaccinated child (3 doses)$26.0[45]
 IRS unit cost per person protected$5.3[46, 47]
 Household consumption expenditure Q1–Q5, A$227, 369, 499, 671, 1422; 638[48]
 Share of food in total consumption expenditure Q1–Q5, A48, 54, 51, 51, 58, 54%[23]
 GDP per capita 2016$713[38]
  1. aQ1 stands for poorest income quintile, Q5 for richest income quintile, and A for average
  2. bAverage unit cost estimate for inpatient visit
\